The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism

Essentials The risk of bleeding influences the duration of anticoagulation (AC) after venous thromboembolism. We assessed the ACCP bleeding risk score in an inception‐cohort of patients receiving AC. 53% were categorized at high‐risk, but their bleeding rate was low during long‐term AC. ACCP score had low predictive value for bleeding.

[1]  W. Ageno,et al.  The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: reply , 2018, Journal of thrombosis and haemostasis : JTH.

[2]  Joshua D. Brown,et al.  Risk Stratification for Bleeding Complications in Patients With Venous Thromboembolism: Application of the HAS‐BLED Bleeding Score During the First 6 Months of Anticoagulant Treatment , 2018, Journal of the American Heart Association.

[3]  T. Chao,et al.  Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors , 2018, Thrombosis and Haemostasis.

[4]  J. Rivera‐Caravaca,et al.  Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial , 2017, Thrombosis and Haemostasis.

[5]  G. Guyatt,et al.  Discrimination and Calibration of Clinical Prediction Models: Users’ Guides to the Medical Literature , 2017, JAMA.

[6]  P. Wells,et al.  Bleeding risk in patients with unprovoked venous thromboembolism: A critical appraisal of clinical prediction scores. , 2017, Thrombosis research.

[7]  M. Fang,et al.  Scoring Systems for Estimating the Risk of Anticoagulant-Associated Bleeding , 2017, Seminars in Thrombosis and Hemostasis.

[8]  F. Klok,et al.  External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism , 2017, Thrombosis and Haemostasis.

[9]  P. Reitsma,et al.  Brave real world , 2016, Journal of thrombosis and haemostasis : JTH.

[10]  D. Lane,et al.  Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores , 2016, Journal of thrombosis and haemostasis : JTH.

[11]  S. Schulman,et al.  Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment , 2016, European Respiratory Journal.

[12]  W. Ageno,et al.  Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH , 2016, Journal of thrombosis and haemostasis : JTH.

[13]  S. Yusuf,et al.  The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study , 2016, The Lancet.

[14]  G. Lip,et al.  The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE , 2016, Thrombosis and Haemostasis.

[15]  S. Schulman,et al.  Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[16]  N. Magrini,et al.  The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation , 2015, PloS one.

[17]  P. Prandoni,et al.  D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. , 2014, Blood.

[18]  F. Pomero,et al.  Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism , 2014, Thrombosis and Haemostasis.

[19]  P. Prandoni,et al.  Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry , 2014, Internal and Emergency Medicine.

[20]  G. Raskob,et al.  Apixaban for extended treatment of venous thromboembolism. , 2013, The New England journal of medicine.

[21]  S. Goldhaber,et al.  Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. , 2013, The New England journal of medicine.

[22]  E. Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[23]  R. Gans,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2011, The New England journal of medicine.

[24]  Gregory Y H Lip,et al.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.

[25]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[26]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[27]  M. Monreal,et al.  Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry , 2008, Thrombosis and Haemostasis.

[28]  S. Pocock,et al.  Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, BMJ : British Medical Journal.

[29]  Matthias Egger,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.

[30]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[31]  Keith C. Norris,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  M. Prins,et al.  Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. , 1999, Archives of internal medicine.

[33]  R. Beyth,et al.  Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. , 1998, The American journal of medicine.

[34]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[35]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[36]  L Goldman,et al.  Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. , 1989, The American journal of medicine.

[37]  F. García-Bragado Dalmau.  [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism]. , 2013, Revista clinica espanola.

[38]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .